Kintor Pharmaceutical Limited
Kintor Pharmaceutical Limited (KNTPF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
kntpf · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Kintor Pharmaceutical Limited (KNTPF) measures how much investors pay for each dollar of the company's trailing earnings. KNTPF's current PE ratio of N/A is calculated by dividing its stock price of $0.57 by its TTM earnings per share of -$0.43.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2014 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Kintor Pharmaceutical LimitedYou KNTPF | $265M | N/A | — | -$0.43 |
 Nuo Therapeutics, Inc. AURX | $48M | N/A | — | -$0.05 |
 Hofseth BioCare ASA HOFBF | $66M | N/A | — | -$0.33 |
 Innate Pharma S.A. IPHYF | $211M | N/A | — | -$0.55 |
 Imugene Limited IUGNF | $43M | N/A | — | -$0.32 |
 Satellos Bioscience Inc. MSCLF | $97M | N/A | — | -$20.45 |
 Paradigm Biopharmaceuticals Limited PBIGF | $46M | N/A | — | -$0.06 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.43 | — | |
2024-12-31 FY2024 | — | $-0.36 | — | |
2023-12-31 FY2023 | — | $-2.47 | — | |
2022-12-31 FY2022 | — | $-2.53 | — | |
2021-12-31 FY2021 | — | $-2.36 | — | |
2020-12-31 FY2020 | — | $-1.64 | — | |
2019-12-31 FY2019 | — | $-0.97 | — | |
2018-12-31 FY2018 | — | $-0.00 | — | |
2017-12-31 FY2017 | — | $-0.24 | — | |
2016-12-31 FY2016 | — | $-0.29 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Kintor Pharmaceutical Limited (KNTPF) measures how much investors pay for each dollar of the company's trailing earnings. KNTPF's current PE ratio of N/A is calculated by dividing its stock price of $0.57 by its TTM earnings per share of -$0.43.
Frequently asked questions
KNTPF pe ratio · 6 questionsKNTPF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.57 and TTM EPS of -$0.43. Data sourced from Financial Modeling Prep via KNTPF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Kintor Pharmaceutical Limited SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09